With Final Data Unveiled, Vertex Will Move Its CF Combo Into Pivotal Trials In 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite controversies about incorrectly reported data and allegations of incomplete data, Vertex has demonstrated lung function benefit for a combination of Kalydeco and VX-809 in Phase II and will move the combination into Phase III trials early next year.
You may also be interested in...
Uncertain About HCV, Vertex Doubles Down On CF, Looks To Sell Off Pipeline Assets
As it nears a crucial inflexion point for its hepatitis C business, Vertex shifts focus to building on its strong early start in cystic fibrosis. The Boston-area firm plans to out-license its mid-stage candidates for autoimmune disease and influenza A.
Analysts Miffed By Vertex’s Lack Of Transparency With CF Combo Data
Vertex Pharmaceuticals presented top-line data for its drug combination in cystic fibrosis, but analysts are wondering why the company was not forthcoming about the full data set.
Vertex’s CF Therapy Combination Trial Yields Promising Lung-Function Data
Interim data from a Phase II study investigating Kalydeco with VX-809 showed statistically significant FEV-1 improvement across dosing groups; the company hopes to start a pivotal Phase III program for the combo in late 2012 or early 2013.